

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	--	--	--	---

Service Category:

- | | |
|--|---|
| ☐ Anesthesia
☐ Surgery
☐ Radiology Procedures
☐ Pathology and Laboratory Procedures | ☐ Medicine Services and Procedures
☐ Evaluation and Management Services
☐ DME/Prosthetics or Supplies
☒ Other: Part B Drugs |
|--|---|

Service Description:

This document addresses the use of white blood cell growth factors, also known as colony stimulating factors (CSF). There are two types of CSFs, granulocyte and granulocyte-macrophage. Granulocyte colony stimulating factors (G-CSF) are glycoproteins which exert major control over the reproduction and maturation of certain white blood cells. Granulocyte-macrophage colony stimulating factor (GM-CSF) is a hematopoietic growth factor that stimulates proliferation and differentiation of hematopoietic progenitor cells.

The following agents are included in the class.

- G-CSF:
 - Granix (tbo-filgrastim)
 - Neulasta Onpro/Neulasta (pegfilgrastim) and Biosimilars
 - Armlupeg (pegfilgrastim-unne)
 - Fulphila (pegfilgrastim- jmdb)
 - Fylnetra (pegfilgrastim-pbbk)
 - Nyvepria (pegfilgrastim-apgf)
 - Stimufend (pegfilgrastim-fpgk)
 - Udenyca/Udenyca Onbody (pegfilgrastim-cbqv)
 - Ziextenzo (pegfilgrastim-bmez)
 - Neupogen (filgrastim) and Biosimilars
 - Filkri (filgrastim-laha)
 - Nivestym (filgrastim-aafi)
 - Nypozi (filgrastim-txid)
 - Releuko (filgrastim-ayow)
 - Zarxio (filgrastim-sndz)
 - Rolvedon (eflapegrastim-xnst)
 - Ryzneuta (efbemalenograstim alfa-vuxw)
- GM-CSF
 - Leukine (sargramostim)

Background Information:

Ryzneuta (efbemalenograstim-alfa)

Ryzneuta is a leukocyte growth factor FDA indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Ryzneuta is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. National

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	--	--	--	---

Comprehensive Cancer Network (NCCN) provides a 2A recommendation for the treatment of patients with radiation-induced myelosuppression following a radiologic/nuclear incident (hematopoietic acute radiation syndrome [H- ARS]).

Rolvedon (eflapregrastim-xnst)

Rolvedon is a nonbiosimilar long-acting hematopoietic growth factor consisting of a recombinant human granulocyte-colony stimulating factor (rhG-CSF) analog conjugated to a human IgG4Fc fragment. The addition of the Fc fragment extend the drug's half-life, which has been used in other marketed biologics (e.g. etanercept). Rolvedon is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. Rolvedon is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. NCCN also provides a 2A recommendation for the treatment of patients with radiation-induced myelosuppression following a radiologic/nuclear incident (hematopoietic acute radiation syndrome [H-ARS]).

Primary prophylaxis of chemotherapy-induced febrile neutropenia

Neutropenia with fever (febrile neutropenia [FN]) is a serious consequence of myelosuppressive chemotherapy that usually results in hospitalization and the need for intravenous antibiotics (Lyman 2014). FN may result in dose reductions, delays, or even discontinuation of chemotherapy, which, in turn, may compromise patient outcomes. It is important to identify which patients are at high risk for developing FN so that patients can receive optimal chemotherapy while their risk for FN is appropriately managed. There are many factors that need to be evaluated to determine a patient's risk of developing FN, which includes type of chemotherapy regimen, type of cancer being treated, and other patient-specific risk factors.

A review of the literature was performed to gain a comprehensive and updated understanding of FN risk associated with chemotherapy regimens and patient-specific FN risk factors. Studies that have analyzed FN risk factors, often have several limitations, including their retrospective nature and small sample sizes. Our assessment of the following patient risk factors and chemotherapy regimens ([see appendix](#) below) is after a review of published literature and guidelines from the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN).

The patient risk factors for the development of febrile neutropenia include:

- Age greater than 65 years (Lyman 2014; Aagaard 2018); **OR**
- Poor performance status (Eastern Cooperative Oncology Group 3 or 4) or HIV infection (in particular, those with low CD4 counts ($\leq 450/\mu\text{L}$)) but chemotherapy still indicated (Lyman 2014); **OR**
- Prior radiation therapy (within previous 1 year) (Terbuch 2018) (Fujiwara 2017) (Shigeta 2015); **OR**
- Bone marrow involvement by tumor producing cytopenias (Lyman 2014); **OR**
- Persistent neutropenia (absolute neutrophil count [ANC] less than $1500/\text{mm}^3$) (Lyman 2014); **OR**
- Poor renal function (glomerular filtration rate [GFR] less than $60\text{mL}/\text{min}$) (Lyman 2014; Aagaard 2018); **OR**
- Liver dysfunction (liver function tests (AST or ALT levels) at least 2X upper limit of normal or bilirubin $> 2.0\text{ mg}/\text{dL}$) (Lyman 2014; Aagaard 2018); **OR**

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	--	--	--	---

- Recent surgery performed as part of cancer management within previous 30 days (not to include a procedure such as port placement, drain placement, IVC filter, etc.) (Lyman 2014; Aagaard 2018); **OR**
- History of active infection within previous 60 days (Lyman 2014; Aagaard 2018); **OR**
- Current open wound and chemotherapy cannot be delayed (Lyman 2014; Aagaard 2018).

Classic Hodgkin Lymphoma

NCCN provides a 2A recommendation for use of filgrastim, pegfilgrastim, and tbo-filgrastim in classic Hodgkin lymphoma in combination with brentuximab vedotin in adults. Pediatric Aggressive Mature B-cell Lymphomas A G-CSF agent may be provided for an ANC < 1x 10⁹/l during chemotherapy treatments (e.g with etoposide, doxorubicin, and cyclophosphamide or CHOP).

Zynteglo (betibeglogene autotemcel) Gene Therapy

Before administration of Zynteglo, hematopoietic stem cells are mobilized with granulocyte colony-stimulating factor and plerixafor, and cells are collected by apheresis. In clinical trials, up to two mobilization cycles (separated by at least 2 weeks) were performed, determined by the need to reach the cumulated target collection number needed for beti-cel manufacture or manufacturing and for rescue cells cryopreserved and stored on site. Prior to apheresis, transfusions are recommended to obtain 8 hemoglobin levels of at least 11 g per deciliter; this hemoglobin level is recommended to be maintained during mobilization and apheresis to suppress stress erythropoiesis.

Mozobil for hematopoietic Stem Cell Mobilization

NCCN provides a 2A recommendation for the use of plerixafor in the treatment for hematopoietic cell mobilization for autologous donors in combination with filgrastim, filgrastim + cyclophosphamide, sargramostim +cyclophosphamide, or pegfilgrastim. NCCN provides a 2A recommendation for the use of motixafortide in the treatment for hematopoietic cell mobilization for autologous donors with filgrastim. NCCN also provides additional use for insufficient collection of stem cells in combination with either filgrastim (tbo-filgrastim or its biosimilars) alone or filgrastim (or tbo-filgrastim/or its biosimilars) and disease-specific chemotherapy.

Consider as additional supportive care for neutropenic patients

The use of G-CSF has been suggested in the NCCN guidelines as a 2A recommendation in supportive care for Grade 1 fever in those using CAR T-cell therapy to prevent progression of cytokine release syndrome (CRS). A small retrospective analysis in diffuse large B- cell lymphoma members using G-CSF during CAR-T therapy (Gaut 2019) showed no difference in the incidence and severity of infection or incidence of developing CRS between those who received G-CSF and those that did not.

Wilms Tumor (favorable history)

NCCN recommends the use of G-CSF has been suggested for use as supportive care in Wilms Tumor (nephroblastoma) after doses of myelosuppressive agents after courses of cyclophosphamide and etoposide and cyclophosphamide, doxorubicin, and vincristine in Regimen M and Regimen I.

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023	Effective Date: 08/19/2026
			Last Review Date: 08/19/2026	Frequently Revision: Annual

Definitions and Measures

- Absolute neutrophil count (ANC): A measure of the number of neutrophils (a type of white blood cell) in the blood.
- Acute Radiation Syndrome (ARS): Also known as radiation sickness.
- Adjuvant or adjunctive treatment: Treatment given after the primary treatment to increase the chances of a cure and may include chemotherapy, radiation, hormone or biological therapy.
- Febrile neutropenia: Febrile neutropenia can occur as a result of severe neutropenia; defined as the occurrence of fever (greater than or equal to 38.3°C for more than 1 hour) in association with an ANC less than $0.5 \times 10^9/L$ or ANC less than $1.0 \times 10^9/L$ and a predicted decline to less than or equal to $0.5 \times 10^9/L$ over the subsequent 48 hours.
- ECOG or Eastern Cooperative Oncology Group Performance Status: A scale and criteria used by doctors and researchers to assess how an individual's disease is progressing, assess how the disease affects the daily living abilities of the individual, and determine appropriate treatment and prognosis. This scale may also be referred to as the WHO (World Health Organization) or Zubrod score which is based on the following scale:
 - 0 = Fully active, able to carry on all pre-disease performance without restriction
 - 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, for example, light house work, office work
 - 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours
 - 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
 - 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair
 - 5 = Dead
- Neutropenia: A decrease in the number of neutrophils (white blood cells that respond quickly to infection) in the blood. Neutrophils less than 1,500/mm³ is considered to be neutropenic and at risk for infection. Neutrophils fewer than 500 cells/mm³ is considered at high risk of infection.
- Neutrophil: A type of white blood cell that helps fight infection.
- Primary prophylaxis: Prevention of febrile neutropenia with the first cycle of a specified chemotherapy regimen.
- Secondary prophylaxis: Prevention of febrile neutropenia given with the second and/or subsequent cycle of a given regimen of chemotherapy for individuals who had a neutropenic complication from the preceding cycle of chemotherapy and there is no plan to reduce the dose intensity.

Approved Indications

- A. See Background Information above.

Other Uses

- A. Use of G-CSF agents in damaged myocardium

The use of G-CSF has been proposed as an adjunct to standard therapies to promote mobilization of stem cells and progenitor cells from the bone marrow into the circulating blood to improve repair of the damaged myocardium. The benefits of G-CSF in other fields, such as oncology, has led to research

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
---	---	--	--	---

assessing the potential of G-CSF in repairing myocardial tissue and improving clinical outcomes in those with damaged hearts. To date, the published evidence regarding the safety and efficacy of G-CSF has been lacking.

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
---	---	--	--	---

Medical Necessity Guidelines:

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Eflapegrastim-xnst (Rolvedon)

- A. Criteria For Initial Approval** (*Provider must submit documentation [such as office chart notes, lab results, pathology reports, imaging studies, and any other pertinent clinical information] supporting the patient's diagnosis for the drug and confirming that the patient has met **all** approval criteria.*)

Requests for Rolvedon (eflapegrastim-xnst) may be approved if the following criteria are met:

- i. Individual with nonmyeloid malignancy is using for primary prophylaxis of Febrile Neutropenia (FN); **AND**
 - ii. Individual has a risk of FN of 20% or greater based on chemotherapy regimen (NCCN 2A) ([see Appendix](#), Table 1);
- OR**
- iii. Individual with nonmyeloid malignancy is using for primary prophylaxis of FN; **AND**
 - iv. Individual has a risk of developing FN is greater than or equal to 10% and less than 20% based on chemotherapy regimen ([see Appendix](#), Table 1) and individuals have any of the following risk factors for FN:
 - A. Age greater than 65 years (Lyman 2014; Aagaard 2018); **OR**
 - B. Poor performance status (Eastern Cooperative Oncology Group 3 or 4) or HIV infection (in particular, those with low CD4 counts ($\leq 450/\mu\text{L}$)) but chemotherapy still indicated (Lyman 2014); **OR**
 - C. Prior radiation therapy (within previous 1 year) (Terbuch 2018) (Fujiwara 2017) (Shigeta 2015); **OR**
 - D. Bone marrow involvement by tumor producing cytopenias (Lyman 2014); **OR**
 - E. Persistent neutropenia (absolute neutrophil count [ANC] less than 1500/mm³) (Lyman 2014); **OR**
 - F. Poor renal function (glomerular filtration rate [GFR] less than 60mL/min) (Lyman 2014; Aagaard 2018); **OR**
 - G. Liver dysfunction (liver function tests (AST or ALT levels) at least 2X upper limit of normal or bilirubin > 2.0 mg/dL) (Lyman 2014) (Aagaard 2018); **OR**
 - H. Recent surgery performed as part of cancer management within previous 30 days (not to include a procedure such as port placement, drain placement, IVC filter, etc.) (Lyman 2014; Aagaard 2018); **OR**
 - I. History of active infection within previous 60 days (Lyman 2014; Aagaard 2018); **OR**
 - J. Current open wound and chemotherapy cannot be delayed (Lyman 2014; Aagaard 2018).

OR

- v. Individual with nonmyeloid malignancy is using for secondary prophylaxis of FN; **AND**

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	--	--	--	---

- vi. Individual has experienced a neutropenic complication from a prior cycle of chemotherapy (for which prophylaxis was not received), in which a reduced dose may compromise disease-free or overall survival or treatment outcome (NCCN 2A);

OR

- vii. Individual is using as adjunctive treatment for FN; **AND**
viii. Individual has not received prophylactic therapy with pegfilgrastim (NCCN 2A); **AND**
ix. Individual has a high risk for infection-associated complications as demonstrated by any of the following:
- A. Expected prolonged (greater than 10 days) and profound (less than $0.1 \times 10^9/L$) neutropenia; **OR**
 - B. Age greater than 65 years; **OR**
 - C. Pneumonia or other clinically documented infections; **OR**
 - D. Hypotension and multi organ dysfunction (sepsis syndrome); **OR**
 - E. Invasive fungal infection; **OR**
 - F. Prior episode of febrile neutropenia; **OR**
 - G. Hospitalized at the time of the development of fever;

OR

- x. Individual is using after accidental or intentional total body radiation of myelosuppressive doses (greater than 2 Grays [Gy]) (such as Hematopoietic Syndrome of Acute Radiation Syndrome) (NCCN 2A).

OR

- xi. Individual is using for prophylaxis of febrile neutropenia due to immune effector cell (IEC) therapies (NCCN 2A) in the following groups:
- A. Individual has an overall risk score of low (0 risk factors) but develop immune effector cell-associated hematologic toxicity (ICAHT) with severe neutropenia ($<500 \text{ uL}$) for ≥ 7 days within the first 30 days post-infusion; **OR**
 - B. Individual has an overall risk score of low (0 risk factors) but develop ICAHT with recurrent neutropenia ($<1000/\text{uL}$) not explained by another etiology beyond 30 days post-infusion; **OR**
 - C. Individual is ≥ 2 days post-infusion if an overall risk score of high (≥ 1 risk factors); **OR**
 - D. Individual has ≥ 1 risk factors and /or cytopenias beyond 21 days post-infusion for suspected ICAHT in those receiving IEC therapies.

Efbemalenograstim alfa-vuxw (Ryzneuta)

Requests for Ryzneuta (efbemalenograstim alfa-vuxw) may be approved if the following criteria are met:

- i. Individual with nonmyeloid malignancy is using for primary prophylaxis of Febrile Neutropenia (FN); **AND**
- ii. Individual has a risk of FN of 20% or greater based on chemotherapy regimen (NCCN 2A) ([see Appendix, Table 1](#));
- iii. Individual with nonmyeloid malignancy is using for primary prophylaxis of FN; **AND**

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
---	---	--	--	---

- iv. Individual has a risk of developing FN is greater than or equal to 10% and less than 20% based on chemotherapy regimen ([see Appendix](#), Table 1) and individuals have any of the following risk factors for FN:
- A. Age greater than 65 years (Lyman 2014; Aagaard 2018); **OR**
 - B. Poor performance status (Eastern Cooperative Oncology Group 3 or 4) or HIV infection (in particular, those with low CD4 counts ($\leq 450/\mu\text{L}$)) but chemotherapy still indicated (Lyman 2014); **OR**
 - C. Prior radiation therapy (within previous 1 year) (Terbuch 2018) (Fujiwara 2017) (Shigeta 2015); **OR**
 - D. Bone marrow involvement by tumor producing cytopenias (Lyman 2014); **OR**
 - E. Persistent neutropenia (absolute neutrophil count [ANC] less than 1500mm^3) (Lyman 2014); **OR**
 - F. Poor renal function (glomerular filtration rate [GFR] less than 60mL/min) (Lyman 2014; Aagaard 2018); **OR**
 - G. Liver dysfunction (liver function tests at least (AST or ALT levels) 2X upper limit of normal or bilirubin $> 2.0\text{ mg/dL}$) (Lyman 2014) (Aagaard 2018); **OR**
 - H. Recent surgery performed as part of cancer management within previous 30 days (not to include a procedure such as port placement, drain placement, IVC filter, etc.) (Lyman 2014; Aagaard 2018); **OR**
 - I. History of active infection within previous 60 days (Lyman 2014; Aagaard 2018); **OR**
 - J. Current open wound and chemotherapy cannot be delayed (Lyman 2014; Aagaard 2018).

OR

- v. Individual with nonmyeloid malignancy is using for secondary prophylaxis of FN; **AND**
- vi. Individual has experienced a neutropenic complication from a prior cycle of chemotherapy (for which prophylaxis was not received), in which a reduced dose may compromise disease-free or overall survival or treatment outcome (NCCN 2A);

OR

- vii. Individual is using as adjunctive treatment for FN; **AND**
- viii. Individual has not received prophylactic therapy with pegfilgrastim (NCCN 2A); **AND**
- ix. Individual has a high risk for infection-associated complications as demonstrated by any of the following:

- A. Expected prolonged (greater than 10 days) and profound (less than $0.1 \times 109/\text{L}$) neutropenia; **OR**
- B. Age greater than 65 years; **OR**
- C. Pneumonia or other clinically documented infections; **OR**
- D. Hypotension and multi organ dysfunction (sepsis syndrome); **OR**
- E. Invasive fungal infection; **OR**
- F. Prior episode of febrile neutropenia; **OR**
- G. Hospitalized at the time of the development of fever;

OR

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
---	---	--	--	---

- x. Individual is using after accidental or intentional total body radiation of myelosuppressive doses (greater than 2 Grays [Gy]) (such as Hematopoietic Syndrome of Acute Radiation Syndrome) (NCCN 2A).
- OR**
- xi. Individual is using for prophylaxis of febrile neutropenia due to immune effector cell (IEC) therapies (NCCN 2A) in the following groups:
 - A. Individual has an overall risk score of low (0 risk factors) but develop immune effector cell associated hematologic toxicity (ICAHT) with severe neutropenia (<500 uL) for ≥ 7 days within the first 30 days post-infusion; **OR**
 - B. Individual has an overall risk score of low (0 risk factors) but develop ICAHT with recurrent neutropenia (<1000/uL) not explained by another etiology beyond 30 days post-infusion; **OR**
 - C. Individual is ≥ 2 days post-infusion if an overall risk score of high (≥ 1 risk factors); **OR**
 - D. Individual has ≥ 1 risk factors and /or cytopenias beyond 21 days post-infusion for suspected ICAHT in those receiving IEC therapies.

Neulasta/Neulasta Onpro (pegfilgrastim), Armlupeg (pegfilgrastim-unne), Fulphila (pegfilgrastim-jmdb), Fylnetra (pegfilgrastim-pbbk), Nyvepria (pegfilgrastim- apgf), Stimufend (pegfilgrastim-fpgk), Udenyca/Udenyca Onbody (pegfilgrastim-cbqv), or Ziextenzo (pegfilgrastim-bmez

Requests for Neulasta/Neulasta Onpro (pegfilgrastim), Armlupeg (pegfilgrastim-unne), Fulphila (pegfilgrastim-jmdb), Fylnetra (pegfilgrastim-pbbk), Nyvepria (pegfilgrastim-apgf), Stimufend (pegfilgrastim-fpgk), Udenyca/Udenyca Onbody (pegfilgrastim-cbqv), or Ziextenzo (pegfilgrastim-bmez) may be approved if the following criteria are met:

- i. Individual with nonmyeloid malignancy is using for primary prophylaxis of Febrile Neutropenia (FN); **AND**
 - ii. Individual has a risk of FN of 20% or greater based on chemotherapy regimen ([see Appendix, Table 1](#));
- OR**
- iii. Individual with nonmyeloid malignancy is using for primary prophylaxis of FN; **AND**
 - iv. Individual's risk of developing FN is greater than or equal to 10% and less than 20% based on chemotherapy regimen ([see Appendix, Table 1](#)) and individual has any of the following risk factors for FN:
 - A. Age greater than 65 years (Lyman 2014; Aagaard 2018); **OR**
 - B. Poor performance status (Eastern Cooperative Oncology Group 3 or 4) or HIV infection (in particular, those with low CD4 counts ($\leq 450/\mu\text{L}$)) but chemotherapy still indicated (Lyman 2014); **OR**
 - C. Prior radiation therapy (within previous 1 year) (Terbuch 2018) (Fujiwara 2017) (Shigeta 2015); **OR**
 - D. Bone marrow involvement by tumor producing cytopenias (Lyman 2014); **OR**
 - E. Persistent neutropenia (absolute neutrophil count [ANC] less than 1500/mm³) (Lyman 2014); **OR**

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	--	--	--	---

- F. Poor renal function (glomerular filtration rate [GFR] less than 60mL/min) (Lyman 2014; Aagaard 2018); **OR**
- G. Liver dysfunction (liver function tests (AST or ALT levels) at least 2X upper limit of normal or bilirubin > 2.0 mg/dL) (Lyman 2014) (Aagaard 2018); **OR**
- H. Recent surgery performed as part of cancer management within previous 30 days (not to include a procedure such as port placement, drain placement, IVC filter, etc) (Lyman 2014; Aagaard 2018); **OR**
- I. History of active infection within previous 60 days (Lyman 2014; Aagaard 2018); **OR**
- J. Current open wound and chemotherapy cannot be delayed (Lyman 2014; Aagaard 2018);

OR

- v. Individual with nonmyeloid malignancy is using for secondary prophylaxis of FN; **AND**
- vi. Individual has experienced a neutropenic complication from a prior cycle of chemotherapy (for which prophylaxis was not received), in which a reduced dose may compromise disease-free or overall survival or treatment outcome (NCCN 2A);

OR

- vii. Individual is using as adjunctive treatment for FN; **AND**
- viii. Individual has not received prophylactic therapy with pegfilgrastim (NCCN 2A); **AND**
- ix. Individual has a high risk for infection-associated complications as demonstrated by any of the following:
 - A. Expected prolonged (greater than 10 days) and profound (less than $0.1 \times 10^9/L$) neutropenia; **OR**
 - B. Age greater than 65 years; **OR**
 - C. Pneumonia or other clinically documented infections; **OR**
 - D. Hypotension and multi organ dysfunction (sepsis syndrome); **OR**
 - E. Invasive fungal infection; **OR**
 - F. Prior episode of febrile neutropenia; **OR**
 - G. Hospitalized at the time of the development of fever

OR

- x. Individual has a diagnosis of Classic Hodgkin lymphoma (age 18-60 years) (NCCN 2A); **AND**
 - A. Individual is using in combination with brentuximab vedotin with AVD; **OR**
 - B. Individual is using in combination with brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone;

OR

- xi. Individual has a diagnosis of Pediatric Aggressive Mature B-Cell Lymphomas (NCCN 2A);

OR

- xii. Individual has a diagnosis of Pediatric Classic Hodgkin Lymphoma (NCCN 2A);

OR

- xiii. Individual is receiving dose dense therapy (treatment given more frequently, such as every 2 weeks instead of every 3 weeks) for adjuvant treatment of breast cancer (ASCO Smith 2015);

OR

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	--	--	--	---

- xiv. Individual is using after accidental or intentional total body radiation of myelosuppressive doses (greater than 2 Grays [Gy]) (such as Hematopoietic Syndrome of Acute Radiation Syndrome) (Label, NCCN 2A);
- OR**
- xv. Individual is using after a hematopoietic progenitor stem cell transplant (HPCT/HSCT) to promote myeloid reconstitution OR when engraftment is delayed or has failed (NCCN 2A);
- OR**
- xvi. Individual is using for treatment for hematopoietic cell mobilization in combination with plerixafor (NCCN 2A);
- OR**
- xvii. Individual is using for Wilms Tumor (Nephroblastoma) (NCCN 2A); **AND**
- xviii. Using with Regimen M and Regimen I for one of the following courses:
 - A. Cyclophosphamide and etoposide; **OR**
 - B. Cyclophosphamide, doxorubicin, and vincristine;
- OR**
- xix. Individual is using for autologous hematopoietic stem cell (HSC) mobilization as part of the development of an FDA-approved ex vivo gene therapy (e.g. Zynteglo (betibeglogene autoemcel)).
- OR**
- xx. Individual is using for prophylaxis of febrile neutropenia due to immune effector cell (IEC) therapies (NCCN 2A) in the following groups:
 - A. Individual has an overall risk score of low (0 risk factors) but develop immune effector cell associated hematologic toxicity (ICAHT) with severe neutropenia (<500 uL) for ≥ 7 days within the first 30 days post-infusion; **OR**
 - B. Individual has an overall risk score of low (0 risk factors) but develop ICAHT with recurrent neutropenia (<1000/uL) not explained by another etiology beyond 30 days post-infusion; **OR**
 - C. Individual is ≥ 2 days post-infusion if an overall risk score of high (≥ 1 risk factors); **OR**
 - D. Individual has ≥ 1 risk factors and /or cytopenias beyond 21 days post-infusion for suspected ICAHT in those receiving IEC therapies.

Neupogen (filgrastim), Filkri (filgrastim-laha), Nivestym (filgrastim-aafi), Nypozi (filgrastim-txid), Releuko (filgrastim-ayow), or Zarxio (filgrastim-sndz)

Requests for Neupogen (filgrastim), Filkri (filgrastim-laha), Nivestym (filgrastim-aafi), Nypozi (filgrastim-txid), Releuko (filgrastim-ayow), or Zarxio (filgrastim-sndz) may be approved if the following criteria are met:

- i. Individual with nonmyeloid malignancy is using for primary prophylaxis of FN; **AND**
- ii. Individual has a risk of FN of 20% or greater based on chemotherapy regimen ([see Appendix, Table 1](#));
- OR**
- iii. Individual with nonmyeloid malignancy is using for primary prophylaxis of FN; **AND**

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	--	--	--	---

- iv. Individual's risk of developing FN is greater than or equal to 10% and less than 20% based on chemotherapy regimen ([see Appendix](#), Table 1) and individual has any risk factors for FN:
- A. Age greater than 65 years (Lyman 2014; Aagaard 2018); **OR**
 - B. Poor performance status (Eastern Cooperative Oncology Group 3 or 4) or HIV infection (in particular, those with low CD4 counts ($\leq 450/\mu\text{L}$) but chemotherapy still indicated (Lyman 2014); **OR**
 - C. Prior radiation therapy (within previous 1 year) (Terbuch 2018) (Fujiwara 2017) (Shigeta 2015); **OR**
 - D. Bone marrow involvement by tumor producing cytopenias (Lyman 2014); **OR**
 - E. Persistent neutropenia (absolute neutrophil count [ANC] less than 1500/mm³) (Lyman 2014); **OR**
 - F. Poor renal function (glomerular filtration rate [GFR] less than 60mL/min) (Lyman 2014) (Aagaard 2018); **OR**
 - G. Liver dysfunction (liver function tests (AST or ALT levels) at least 2X upper limit of normal or bilirubin > 2.0 mg/dL) (Lyman 2014; Aagaard 2018); **OR**
 - H. Recent surgery performed as part of cancer management within previous 30 days (not to include a procedure such as port placement, drain placement, IVC filter, etc) (Lyman 2014; Aagaard 2018); **OR**
 - I. History of active infection within previous 60 days (Lyman 2014; Aagaard 2018); **OR**
 - J. Current open wound and chemotherapy cannot be delayed (Lyman 2014; Aagaard 2018);

OR

- v. Individual with nonmyeloid malignancy is using for secondary prophylaxis of FN; **AND**
- vi. Individual has experienced a neutropenic complication from a prior cycle of chemotherapy (for which prophylaxis was not received), in which a reduced dose may compromise disease-free or overall survival or treatment outcome (NCCN 2A);

OR

- vii. Individual is using as adjunctive treatment for FN (NCCN 2A); **AND**
- viii. Individual has been on prophylactic therapy with filgrastim;

OR

- ix. Individual has not received prophylactic therapy with a granulocyte colony stimulating factor (NCCN Guidelines Myeloid Growth Factors); **AND**
- x. Individual has a high risk for infection-associated complications as demonstrated by any of the following (NCCN 2A):
 - A. Expected prolonged (greater than 10 days) and profound (less than $0.1 \times 10^9/\text{L}$) neutropenia; **OR**
 - B. Age greater than 65 years; **OR**
 - C. Pneumonia or other clinically documented infections; **OR**
 - D. Hypotension and multi organ dysfunction (sepsis syndrome); **OR**
 - E. Invasive fungal infection; **OR**
 - F. Prior episode of febrile neutropenia; **OR**
 - G. Hospitalized at the time of the development of fever;

OR

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	--	--	--	---

x.	Individual has relapsed or refractory adult acute lymphoblastic leukemia (ALL) (NCCN 2A); AND A. Individual has a poor prognosis; AND B. Individual is using in combination with fludarabine, cytarabine, and idarubicin (FLAG-IDA); OR C. Individual is using in combination with fludarabine, cytarabine;
OR	
xii.	Individual has a diagnosis of Pediatric Aggressive Mature B-Cell Lymphomas (NCCN 2A); AND
OR	
xiii.	Individual is 18 years of age or older and has a diagnosis of acute myeloid leukemia (AML); AND
xiv.	Individual is using shortly after the completion of induction or repeat induction chemotherapy, or after the completion of consolidation chemotherapy for AML (Label, NCCN 2A);
OR	
xv.	Individual has a diagnosis of hairy cell leukemia with severe neutropenia (AHFS, NCCN Guidelines Hairy Cell Leukemia);
OR	
xvi.	Individual has a diagnosis of Classic Hodgkin lymphoma (age 18-60 years) (NCCN 2A); AND A. Individual is using in combination with brentuximab vedotin with AVD; OR B. Individual is using in combination with brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone;
OR	
xvii.	Individual has a diagnosis of Pediatric Classic Hodgkin lymphoma (NCCN 2A);
OR	
xviii.	Individual has a diagnosis of myelodysplastic syndrome (MDS) (NCCN 2A); AND
xix.	Individual has severe neutropenia (ANC less than or equal to 500mm ³) or experiencing recurrent or resistant infections;
OR	
xx.	Individual has a diagnosis of myelodysplastic syndrome with ring sideroblasts (MDS-RS) or MDS/MPN-RS-T; AND
xxi.	Individual is using in combination with Reblozyl (Reblozyl Label);
OR	
xxii.	Individual has IPSS-R (Very Low, Low, Intermediate) risk myelodysplastic syndrome associated with symptomatic anemia (NCCN 2A); AND
xxiii.	Individual does not have a del(5q) chromosomal abnormality; AND
xxiv.	Individual has serum erythropoietin ≤ 500 mU/ML; AND
xxv.	Individual will use in combination with an erythropoiesis-stimulating agent (ESA) following no response to either an ESA alone or luspatercept-aamt (Reblozyl);
OR	
xxvi.	Individual is receiving dose dense therapy (treatment given more frequently, such as every 2 weeks instead of every 3 weeks) for adjuvant treatment of breast cancer (ASCO Smith 2015);
OR	

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	--	--	--	---

xxvii.	Individual is using for chronic administration to reduce the incidence and duration of sequelae of neutropenia (for example, fever, infections, oropharyngeal ulcers) in symptomatic individuals with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia;
OR	
xxviii.	Individual is using for the treatment of (non-chemotherapy) drug-induced neutropenia (AHFS);
OR	
xxix.	Individual is less than 21 years of age and is diagnosed with glycogen storage disease type 1b;
AND	
xxx.	Individual is using for the treatment of low neutrophil counts (AHFS);
OR	
xxxi.	Individual is using for the treatment of neutropenia associated with human immunodeficiency virus infection and antiretroviral therapy (AHFS);
OR	
xxxii.	Individual is using after accidental or intentional total body radiation of myelosuppressive doses (greater than 2 Grays [Gy]) (such as Hematopoietic Syndrome of Acute Radiation Syndrome);
OR	
xxxiii.	Individual is using after a hematopoietic progenitor stem cell transplant (HPCT/HSCT) to promote myeloid reconstitution or when engraftment is delayed or has failed (NCCN 2A);
OR	
xxxiv.	Individual is using to mobilize progenitor cells into peripheral blood for collection by leukapheresis, as an adjunct to peripheral blood/hematopoietic stem cell transplantation (PBSCT/PHSCT);
OR	
xxxv.	Individual is using as an alternate or adjunct to donor leukocyte infusions (DLI) in those with leukemic relapse after an allogeneic hematopoietic stem cell transplant (DrugPoints B Iia);
OR	
xxxvi.	Individual is using to reduce the duration of neutropenia and neutropenia related clinical sequelae in those with nonmyeloid malignancies undergoing myeloblastic chemotherapy followed by bone marrow transplant (BMT) (Label);
OR	
xxxvii.	Individual is using for treatment for hematopoietic cell mobilization for autologous donors (NCCN 2A);
OR	
xxxviii.	Individual is using for additional therapy for insufficient collection of stem cells in combination with plerixafor following treatment with filgrastim alone (or its biosimilars) or filgrastim (or its biosimilars) and disease-specific chemotherapy (NCCN 2A);
OR	
xxxix.	Individual is using for Wilms Tumor (Nephroblastoma) (NCCN 2A); AND
xl.	Using with Regimen M and Regimen I for one of the following courses:
	A. Cyclophosphamide and etoposide; OR
	B. Cyclophosphamide, doxorubicin, and vincristine;
OR	

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
---	---	--	--	---

- xli. Individual is using for autologous hematopoietic stem cell (HSC) mobilization as part of the development of an FDA-approved ex vivo gene therapy (e.g. Zynteglo (betibeglogene autoemcel)) (NCCN 2A);
- OR**
- xlii. Individual is using for hematopoietic cell mobilization for allogenic donors as a single agent (NCCN 2A);
- OR**
- xliii. Individual is using as supportive management of neutropenic events due to immunotherapy related toxicities from CAR T-cell therapy (NCCN 2A).
- OR**
- xliv. Individual is using for prophylaxis of febrile neutropenia due to immune effector cell (IEC) therapies (NCCN 2A) in the following groups:
 - A. Individual has an overall risk score of low (0 risk factors) but develop immune effector cell associated hematologic toxicity (ICAHT) with severe neutropenia (<500 uL) for ≥ 7 days within the first 30 days post-infusion; **OR**
 - B. Individual has an overall risk score of low (0 risk factors) but develop ICAHT with recurrent neutropenia (<1000/uL) not explained by another eitology beyond 30 days post-infusion; **OR**
 - C. Individual is ≥ 2 days post-infusion if an overall risk score of high (≥ 1 risk factors); **OR**
 - D. Individual has ≥ 1 risk factors and /or cytopenias beyond 21 days post-infusion for suspected ICAHT in those receiving IEC therapies.

Leukine (Sargramostim)

Requests for Leukine (sargramostim) may be approved if the following criteria are met:

- i. Individual is using as adjunctive treatment for FN: **AND**
- ii. Individual has not previously received prophylactic granulocyte colony-stimulating factors (NCCN 2A); **AND**
- iii. Individual has a high risk for infection-associated complications as demonstrated by any of the following (NCCN 2A):
 - A. Expected prolonged (greater than 10 days) and profound (less than $0.1 \times 10^9/L$) neutropenia; **OR**
 - B. Age greater than 65 years; **OR**
 - C. Pneumonia or other clinically documented infections; **OR**
 - D. Hypotension and multi organ dysfunction (sepsis syndrome); **OR**
 - E. Invasive fungal infection; **OR**
 - F. Prior episode of febrile neutropenia; **OR**
 - G. Hospitalized at the time of the development of fever;
- OR**
- iv. Individual is receiving dose dense therapy (treatment given more frequently, such as every 2 weeks instead of every 3 weeks) for adjuvant treatment of breast cancer (ASCO Smith 2015);

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	--	--	--	---

OR

- v. Individual has a diagnosis of acute myeloid leukemia (AML); **AND**
- vi. Individual is 55 years and older; **AND**
- vii. Individual is using shortly after the completion of induction or repeat induction chemotherapy of AML;

OR

- viii. Individual has a diagnosis of myelodysplastic syndrome (MDS); **AND**
- ix. Individual has severe neutropenia (ANC less than or equal to 500mm³) or experiencing recurrent or resistant infections (NCCN Guidelines Myelodysplastic Syndromes; AHFS);

OR

- x. Individual is 18 years or older; **AND**
- xi. Individual is using for the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation;

OR

- xii. Individual is 2 years of age and older; **AND**
- xiii. Individual is using for the acceleration of myeloid reconstitution following autologous or allogenic bone marrow transplantation or peripheral blood progenitor cell transplantation;

OR

- xiv. Individual is 2 years of age and older; **AND**
- xv. Individual is using for the treatment of delayed neutrophil recovery or graft failure after autologous or allogenic bone marrow transplantation;

OR

- xvi. Individual is using for hematopoietic cell mobilization for autologous donors in combination with cyclophosphamide with or without plerixafor (NCCN 2A);

OR

- xvii. Individual is using to increase survival in adult and pediatric individuals (from birth to 17 years of age) acutely exposed to myelosuppressive doses of radiation (such as Hematopoietic Syndrome of Acute Radiation Syndrome (H-ARS));

OR

- xviii. Individual is 18 years of age or younger; **AND**
- xix. Individual is diagnosed with relapsed/refractory high-risk neuroblastoma; **AND**
- xx. Individual is using in a regimen with dinutuximab (Unituxin) (NCCN 1, 2A); **AND**
- xxi. One of the following:

- A. Individual achieved a partial response to first-line multi-agent, multi-modality therapy (i.e. induction combination chemotherapy, or myeloablative consolidation chemotherapy followed by autologous stem cell transplant); **OR**
- B. Individual is using for post-consolidation therapy, following consolidation therapy for high risk disease and with no disease progression;

OR

- xxii. Individual is diagnosed with relapsed/refractory high-risk neuroblastoma (Danyelza Label); **AND**
- xxiii. Individual is using in combination with Danyelza (naxitamab-gqgk).

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
---	---	--	--	---

Granix (Tbo-Filgrastim)

Requests for Granix (Tbo-Filgrastim) may be approved if the following criteria are met:

- i. Individual with non-myeloid malignancy is using for primary prophylaxis of Febrile Neutropenia (FN); **AND**
 - ii. Individual has a risk of FN of 20% or greater based on chemotherapy regimen ([see Appendix, Table 1](#));
- OR**
- iii. Individual with nonmyeloid malignancy is using for primary prophylaxis of FN; **AND**
 - iv. Individual's risk of developing FN is greater than or equal to 10% and less than 20% based on chemotherapy regimen ([see Appendix, Table 1](#)) and individual has any risk factors for FN:
 - A. Age greater than 65 years (Lyman 2014; Aagaard 2018); **OR**
 - B. Poor performance status (Eastern Cooperative Oncology Group 3 or 4) or HIV infection (in particular, those with low CD4 counts ($\leq 450/\mu\text{L}$)) but chemotherapy still indicated (Lyman 2014); **OR**
 - C. Prior radiation therapy (within previous 1 year) (Terbuch 2018) (Fujiwara 2017) (Shigeta 2015); **OR**
 - D. Bone marrow involvement by tumor producing cytopenias (Lyman 2014); **OR**
 - E. Persistent neutropenia (absolute neutrophil count [ANC] less than 1500/mm³) (Lyman 2014); **OR**
 - F. Poor renal function (glomerular filtration rate [GFR] less than 60mL/min) (Lyman 2014; Aagaard 2018); **OR**
 - G. Liver dysfunction (liver function tests (AST or ALT levels) at least 2X upper limit of normal or bilirubin > 2.0 mg/dL) (Lyman 2014; Aagaard 2018); **OR**
 - H. Recent surgery performed as part of cancer management within previous 30 days (not to include a procedure such as port placement, drain placement, IVC filter, etc.) (Lyman 2014; Aagaard 2018); **OR**
 - I. History of active infection within previous 60 days (Lyman 2014; Aagaard 2018); **OR**
 - J. Current open wound and chemotherapy cannot be delayed (Lyman 2014; Aagaard 2018);
- OR**
- v. Individual with nonmyeloid malignancy is using for secondary prophylaxis of FN; **AND**
 - vi. Individual has experienced a neutropenic complication from a prior cycle of chemotherapy (for which prophylaxis was not received), in which a reduced dose may compromise disease-free or overall survival or treatment outcome (NCCN 2A);
- OR**
- vii. Individual is using as an adjunctive treatment for FN; **AND**
 - viii. Individual was previously using Granix (tbo-filgrastim) prophylactically (NCCN 2A); **OR**
 - ix. Individual has not received prophylactic therapy with a granulocyte colony stimulating factor (NCCN Guidelines Myeloid Growth Factors); **AND**

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	--	--	--	---

x.	Individual has a high risk for infection-associated complications as demonstrated by any of the following: A. Expected prolonged (greater than 10 days) and profound (less than $0.1 \times 10^9/L$) neutropenia (NCCN 2A); OR B. Age greater than 65 years; OR C. Pneumonia or other clinically documented infections; OR D. Hypotension and multi organ dysfunction (sepsis syndrome); OR E. Invasive fungal infection; OR F. Prior episode of febrile neutropenia; OR G. Hospitalized at the time of the development of fever;
OR	
xi.	Individual is using after a hematopoietic progenitor stem cell transplant (HPCT/HSCT) to promote myeloid reconstitution or when engraftment is delayed or has failed (NCCN 2A);
OR	
xii.	Individual has a diagnosis of myelodysplastic syndrome (MDS); AND
xiii.	Individual has severe neutropenia (ANC less than or equal to 500mm^3) or experiencing recurrent or resistant infections (NCCN 2A);
OR	
xiv.	Individual has a diagnosis of myelodysplastic syndrome with ring sideroblasts (MDS-RS) or MDS/MPN-RS-T; AND
xv.	Individual is using in combination with Reblozyl;
OR	
xvi.	Individual has IPSS-R (Very Low, Low, Intermediate) risk myelodysplastic syndrome associated with symptomatic anemia (NCCN 2A); AND
xvii.	Individual does not have a del(5q) chromosomal abnormality; AND
xviii.	Individual has serum erythropoietin $\leq 500 \text{ mU/ML}$; AND
xix.	Individual will use in combination with an erythropoiesis-stimulating agent (ESA) following no response to either an ESA alone or luspatercept-aamt (Reblozyl);
OR	
xx.	Individual has a diagnosis of Classic Hodgkin lymphoma (age 18-60 years) (NCCN 2A); AND A. Individual is using in combination with brentuximab vedotin with AVD; OR B. Individual is using in combination with brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone;
OR	
xxi.	Individual has a diagnosis of Acute Lymphoblastic Leukemia (NCCN 2A);
OR	
xxii.	Individual is using to mobilize progenitor cells into peripheral blood for collection by leukapheresis, as an adjunct to peripheral blood/hematopoietic stem cell transplantation (PBSCT/PHSCT) (AHFS);
OR	
xxiii.	Individual is using after accidental or intentional total body radiation of myelosuppressive doses (greater

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
---	---	--	--	---

xxiv. than 2 Grays [Gy]) (such as Hematopoietic Syndrome of Acute Radiation Syndrome) (NCCN 2A);

OR

xxv. Individual is using for treatment of hematopoietic cell mobilization (for autologous or allogeneic donors) (NCCN 2A);

OR

xxvi. Individual is using for additional therapy for insufficient collection of stem cells in combination with plerixafor following treatment with tbo-filgrastim alone or tbo-filgrastim and disease-specific chemotherapy (NCCN 2A);

OR

xxvii. Individual is using for autologous hematopoietic stem cell (HSC) mobilization as part of the development of an FDA-approved ex vivo gene therapy (e.g. Zynteglo (betibeglogene autoemcel));

OR

xxviii. Individual is using for hematopoietic cell mobilization for autologous donors in combination with Aphexda (motixafortide) (Aphexda Label);

OR

xxix. Individual is using for prophylaxis of febrile neutropenia due to immune effector cell (IEC) therapies (NCCN 2A) in the following groups:

- A. Individual has an overall risk score of low (0 risk factors) but develop immune effector cell associated hematologic toxicity (ICAHT) with severe neutropenia (<500 uL) for ≥ 7 days within the first 30 days post-infusion; **OR**
- B. Individual has an overall risk score of low (0 risk factors) but develop ICAHT with recurrent neutropenia (<1000/uL) not explained by another etiology beyond 30 days post-infusion; **OR**
- C. Individual is ≥ 2 days post-infusion if an overall risk score of high (≥ 1 risk factors); **OR**
- D. Individual has ≥ 1 risk factors and /or cytopenias beyond 21 days post-infusion for suspected ICAHT in those receiving IEC therapies.

B. Criteria For Continuation of Therapy

- i. MMM considers continuation of Colony Stimulating Factors therapy medically necessary for all members (including new members) requesting authorization who meet all initial medical necessity selection criteria.

C. Authorization Duration

- i. Initial and Reauthorization Approval Duration: The Colony Stimulating products covered under this Medical Policy will be approved as requested for the full course of therapy, provided that all initial authorization criteria are met

D. Conditions Not Covered

Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive):

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
---	---	--	--	---

- i. Colony Stimulating Factors (filgrastim and their biosimilars, pegfilgrastim and their biosimilars, sargramostim, and tbo-filgrastim) may not be approved for any of the following:
 - A. Individual is using as prophylaxis for febrile neutropenia, except when above criteria are met; **OR**
 - B. Individual using as treatment for neutropenia in those who are afebrile, except when above criteria are met; **OR**
 - C. Individual is using as adjunctive therapy in those with uncomplicated febrile neutropenia, defined as a fever less than 10 days duration, no evidence of pneumonia, cellulitis, abscess, sinusitis, hypotension, multi-organ dysfunction, or invasive fungal infection, and no uncontrolled malignancies; **OR**
 - D. Individual is using for chemosensitization of myeloid leukemias; **OR**
 - E. Individual is continuing use if no response is seen within 28-42 days (individuals who have failed to respond within this time frame are considered non-responders); **OR**
 - F. Individual is using as a technique to increase the numbers of circulating hematopoietic stem cells as treatment of damaged myocardium.

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
---	---	--	--	---

Limits or Restrictions:

A. Therapeutic Alternatives

The list below includes preferred alternative therapies recommended in the approval criteria and may be subject to prior authorization.

This medical policy may be subject to Step Therapy. Please refer to the document published on the MMM Website: <https://www.mmm-pr.com/planes-medicos/formulario-medicamentos>

B. Quantity Limitations

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. The chart below includes dosing recommendations as per the FDA-approved prescribing information.

Agent(s)	Recommended dosage	Quantity limitation / timing
Neulasta / Neulasta Onpro (pegfilgrastim) - 6 mg/0.6 mL single-dose prefilled syringe - 6 mg/0.6 mL single-dose prefilled syringe co-packaged with the on-body injector (Neulasta Onpro); - 4 mg/0.4 mL single-dose vial	<i>Chemotherapy prophylaxis:</i> adults of any weight and pediatric patients ≥ 45 kg: 6 mg SC once per chemotherapy cycle; pediatric patients < 45 kg: weight-based dosing. <i>Hematopoietic Subsyndrome of Acute Radiation Syndrome (H-ARS):</i> adults and pediatric patients ≥ 45 kg: two 6 mg SC doses one week apart; pediatric patients < 45 kg: weight-based dosing.	1 dose per chemotherapy cycle; do not administer between 14 days before and 24 hours after chemotherapy. For H-ARS, 2 total doses one week apart.
UDENYCA / UDENYCA Onbody (pegfilgrastim-cbqv) - 6 mg/0.6 mL single-dose prefilled syringe - 6 mg/0.6 mL single-dose prefilled autoinjector - 6 mg/0.6 mL single-dose prefilled syringe co-packaged with the on-body injector	<i>Chemotherapy prophylaxis:</i> 6 mg SC once per chemotherapy cycle; pediatric patients < 45 kg: weight-based dosing. <i>H-ARS:</i> two 6 mg SC doses one week apart; pediatric patients < 45 kg: weight-based dosing.	1 dose per chemotherapy cycle; do not administer between 14 days before and 24 hours after chemotherapy. For H-ARS, 2 total doses one week apart.
ARMLUPEG (pegfilgrastim-unne) - 6 mg/0.6 mL single-dose prefilled syringe	<i>Chemotherapy prophylaxis:</i> adults of any weight and pediatric patients ≥ 45 kg: 6 mg SC once per chemotherapy cycle. <i>H-ARS:</i> adults and pediatric patients ≥ 45 kg: two 6 mg SC doses one week apart.	1 dose per chemotherapy cycle; do not administer between 14 days before and 24 hours after chemotherapy. For H-ARS, 2 total doses one week apart.
FULPHILA (pegfilgrastim-jmdb) - 6 mg/0.6 mL single-dose prefilled syringe	<i>Chemotherapy prophylaxis only:</i> 6 mg SC once per chemotherapy cycle; pediatric patients < 45 kg: weight-based dosing.	1 dose per chemotherapy cycle; do not administer between 14

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
---	---	--	--	---

			days before and 24 hours after chemotherapy.
FYLNETRA / STIMUFEND / ZIEXTENZO (pegfilgrastim-pbbk / -fpgk / -bmez) - 6 mg/0.6 mL single-dose prefilled syringe	<i>Chemotherapy prophylaxis:</i> 6 mg SC once per chemotherapy cycle; pediatric patients <45 kg: weight-based dosing. <i>H-ARS:</i> two 6 mg SC doses one week apart.		1 dose per chemotherapy cycle; do not administer between 14 days before and 24 hours after chemotherapy. For H-ARS, 2 total doses one week apart. The syringe is not designed for direct administration of doses <0.6 mL (6 mg).
NYVEPRIA (pegfilgrastim-apgf) - 6 mg/0.6 mL single-dose prefilled syringe	<i>Chemotherapy prophylaxis only:</i> adults of any weight and pediatric patients ≥45 kg: 6 mg SC once per chemotherapy cycle.		1 dose per chemotherapy cycle; do not administer between 14 days before and 24 hours after chemotherapy.
NEUPOGEN / RELEUKO / ZARXIO / NIVESTYM (filgrastim / filgrastim-ayow / filgrastim-sndz / filgrastim-aafi) - 300 mcg/mL single-dose vials, 480 mcg/1.6 mL single-dose vials - 300 mcg/0.5 mL single-dose prefilled syringes - 480 mcg/0.8 mL single-dose prefilled syringes	<i>Chemotherapy or AML induction/consolidation:</i> 5 mcg/kg/day SC or IV daily. <i>Bone marrow transplantation:</i> 10 mcg/kg/day IV. <i>Autologous PBPC mobilization:</i> 10 mcg/kg/day SC. <i>Severe chronic neutropenia:</i> congenital: 6 mcg/kg SC twice daily; cyclic/idiopathic: 5 mcg/kg SC daily. <i>NEUPOGEN / RELEUKO / ZARXIO for H-ARS:</i> 10 mcg/kg/day SC.		Dosing is weight-based and ANC-response driven. For chemotherapy-related use, start at least 24 hours after chemotherapy and do not administer within the 24 hours before chemotherapy.
FILKRI / NYPOZI (filgrastim-laha / filgrastim-txid) - 300 mcg/0.5 mL and 480 mcg/0.8 mL single-dose prefilled syringes	<i>AML:</i> 5 mcg/kg/day SC/IV <i>BMT:</i> 10 mcg/kg/day IV <i>PBPC mobilization:</i> 10 mcg/kg/day SC; <i>SCN:</i> congenital 6 mcg/kg twice daily, cyclic/idiopathic 5 mcg/kg daily. <i>H-ARS:</i> 10 mcg/kg/day SC.		Dosing is weight-based and ANC-response driven. For chemotherapy-related use, start at least 24 hours after chemotherapy and do not administer within the 24 hours before chemotherapy.
GRANIX (tbo-filgrastim) - 300 mcg/0.5 mL single-dose prefilled syringe; 480 mcg/0.8 mL single-dose prefilled syringe; - 300 mcg/1 mL single-dose vial; 480 mcg/1.6 mL single-dose vial	5 mcg/kg/day SC. Continue daily until the expected neutrophil nadir has passed and the neutrophil count has recovered to the normal range.		Dosing is daily and ANC-response driven. First dose no earlier than 24 hours after chemotherapy; do not administer within 24 hours prior to chemotherapy.
ROLVEDON (eflapegrastim-xnst)	13.2 mg SC once per chemotherapy cycle.		1 syringe per chemotherapy cycle; administer

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023	Effective Date: 08/19/2026
			Last Review Date: 08/19/2026	Frequently Revision: Annual

- 13.2 mg/0.6 mL single-dose prefilled syringe		approximately 24 hours after chemotherapy and do not administer from 14 days before to 24 hours after chemotherapy.
RYZNEUTA (efbemalenograstim alfa-vuxw) - 20 mg prefilled single-dose syringe	20 mg SC once per chemotherapy cycle.	1 syringe per chemotherapy cycle; do not administer within 14 days before and <24 hours after chemotherapy.
LEUKINE (sargramostim) - 250 mcg single-dose vial for reconstitution (lyophilized powder) for SC or IV use	<i>AML after induction chemotherapy:</i> 250 mcg/m ² /day IV. <i>PBPC mobilization:</i> 250 mcg/m ² /day IV over 24 hours or SC daily. <i>Post-PBPC transplant:</i> 250 mcg/m ² /day IV over 24 hours or SC daily. <i>Myeloid reconstitution after autologous/allogeneic BMT:</i> 250 mcg/m ² /day IV. <i>Delayed neutrophil recovery/graft failure:</i> 250 mcg/m ² /day for 14 days IV. <i>H-ARS:</i> once-daily SC dosing by weight: >40 kg: 7 mcg/kg; 15–40 kg: 10 mcg/kg; <15 kg: 12 mcg/kg.	Limit is indication-specific and course-specific. Refer to the PI for explicit timing/dose-adjustment instructions by indication.

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	--	--	--	---

Codes Information:

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

ICD-10 Diagnostic Codes:

Codes	Description
C64.0-C64.9	Malignant neoplasm of kidney, except renal pelvis
C74.0-C74.9	Malignant neoplasm of adrenal gland
C81.0-C81.9	Hodgkin lymphoma
C83.30-C83.39, C83.3A	Diffuse large B-cell lymphoma
C83.7	Burkitt lymphoma
C85.1	Unspecified B-cell lymphoma
C91.0	Acute lymphoblastic leukemia [ALL]
C92.0	Acute myeloblastic leukemia
C91.4	Hairy cell leukemia
D46.0-D46.9	Myelodysplastic syndromes
D61.810	Antineoplastic chemotherapy-induced pancytopenia
D70.0	Congenital agranulocytosis
D70.1	Agranulocytosis secondary to cancer chemotherapy
D70.2	Other drug-induced agranulocytosis
D70.3	Neutropenia due to infection
D70.4	Cyclic neutropenia
D70.8	Other neutropenia
D70.9	Neutropenia, unspecified
B20 + D70.-	Human immunodeficiency virus [HIV] disease with neutropenia
E74.01	von Gierke disease
T66.XXXA-T66.XXXS	Radiation sickness, unspecified
Z94.81	Bone marrow transplant status
Z94.84	Stem cells transplant status

HCPCS Codes:

Codes	Description
C9399	Unclassified drugs or biologicals [when specified as Filkri (filgrastim-laha)]
J1442	Injection, filgrastim (G-CSF), excludes biosimilars, 1 mcg [Neupogen]
J1447	Injection, tbo-filgrastim, 1 mcg [Granix]
J1449	Injection, eflapegrastim-xnst, 0.1 mg [Rolvedon]
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg [Neulasta, Neulasta Onpro]
J2820	Injection, sargramostim (GM-CSF), 50 mcg [Leukine]
J3590	Unclassified biologics [when specified as Filkri (filgrastim-laha)]
J9361	Injection, efbemalenograstim alfa-vuxw, 0.5 mg [Ryzneuta]
Q5101	Injection, filgrastim-sndz, biosimilar, (Zarxio), 1 mcg
Q5108	Injection, pegfilgrastim-jmdb (Fulphila), biosimilar, 0.5 mg

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☑ MMM MA ☑ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
---	---	--	--	---

Q5110	Injection, filgrastim-aafi, biosimilar, (Nivestym), 1 mcg
Q5111	Injection, pegfilgrastim-cbqv, biosimilar (Udenyca), 0.5 mg, [Udenyca, Udenyca Onbody]
Q5120	Injection, pegfilgrastim-bmez (ZIEXTENZO), biosimilar, 0.5 mg
Q5122	Injection, pegfilgrastim-apgf (Nyvepria), biosimilar, 0.5 mg
Q5125	Injection, filgrastim-ayow, biosimilar, (Releuko), 1 mcg
Q5127	Injection, pegfilgrastim-fpgk (Stimufend), biosimilar, 0.5 mg
Q5130	Injection, pegfilgrastim-pbbk (Fynetra), biosimilar, 0.5 mg
Q5148	Injection, filgrastim-txid (Nypozi), biosimilar, 1 mcg
Q5169	Injection, pegfilgrastim-unne (Armlupeg), biosimilar, 0.5 mg

CPT Codes:

Codes	Description
96377	Application of on-body injector (includes cannula insertion) for timed subcutaneous injection [Neulasta OnPro injector, Udenyca Onbody]

Appendix

Febrile Neutropenia Risk of Selected Chemotherapy Regimens

The following table represents selected chemotherapy regimens requiring further examination in their disease setting and the associated risk for development of febrile neutropenia. This is not a comprehensive list, as there are other regimens that are associated with risk for the development of FN. The FN risk of these other regimens will follow the guidance within the NCCN Guidelines Management of Neutropenia. A high-risk chemotherapy regimen is defined as a $\geq 20\%$ probability of developing febrile neutropenia, an intermediate-risk chemotherapy regimen is associated with ≥ 10 to $\leq 20\%$ incidence of developing FN, and a low-risk chemotherapy regimen is associated with $<10\%$ incidence of developing FN.

Disease State	Chemotherapy regimen	Risk of developing FN	References
Breast Cancer	Adjuvant TC in those ≥ 65 years old	Intermediate	Do 2015; Jones 2009; Jones 2006; Kosaka 2015; Younis 2012
Breast Cancer (Metastatic)	Fam-trastuzumab deruxtecan-nxki	Low	Modi S et al. 2020; Modi S et al. 2022; Cortes J et al 2022;
Breast cancer (Neoadjuvant)	Pembrolizumab, paclitaxel, and carboplatin	Intermediate	Schmid P, et al. 2022
Breast Cancer (Metastatic)	Pembrolizumab, and chemotherapy	Low	Cortes J, et al 2022; Tolaney SM et al 2021; Tolaney SM et al 2020; Perez-Garcia JM et al 2021; Shah AN et al 2020; de la Cruz-Merino L et al 2022
Breast Cancer	Metastatic Sacituzumab govitecan-hziy	Low	Bardia A et al 2021; Bardia A et al 2019; Rugo HS et al 2022; Kathpalia M et al. 2023

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023	Effective Date: 08/19/2026
			Last Review Date: 08/19/2026	Frequently Revision: Annual

Breast Cancer	Neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, and pertuzumab)	High	Gilbar 2014; Hurvitz 2018
Breast Cancer (Advanced)	Docetaxel (dosing of less than 75 mg/m ²)	Low	Harvey V 2006; Mauri D 2010; Rivera E 2008; Sparano JA 2008; Tabernero J 2004
Breast Cancer (Advanced)	Docetaxel (dosing of 75 mg/m ²)	Intermediate	Andersson M 2011; Baselga J 2012; Burris HA 1999; Harvey V 2006; Jones SE 2005; Marty M 2005;
Castrate-Resistant Prostate Cancer (CRPC) (Advanced)	Cabazitaxel	Intermediate	De Bono JS. 2010; Eisenberger M 2017; Oudard S 2017
Cervical Cancer (Advanced)	Cisplatin and paclitaxel ± bevacizumab	Intermediate	Angioli R 2015; Lissoni AA 2009; Lorusso D 2014; Monk BJ 2009; Moore DH 2004; Tewari KS 2014, 2017; Yang Z 2016
	Topotecan	Intermediate	Bookman MA 2000; Coronel J 2009; Lorusso D 2011; Muderspach LI 2001;
	Pembrolizumab and platinum- based chemotherapy ± bevacizumab	Low	Colombo N et al. 2021
Gastroesophageal Cancer	Cisplatin and irinotecan	Intermediate	Ajani JA 2002; Enzinger PC 2016; Ilson DH 2004, 2012; Knox JJ 2010; Newman E 2005
	Nivolumab and FOLFOX or XELOX	Low	Janjigian YY et al. 2021
Germ Cell Tumors (Advanced)	Bleomycin, etoposide, and cisplatin	Intermediate	de Wit R 2012; Fizazi K 2014; Garcia del Muro X 2008; Nichols CR 1991
	Etoposide and cisplatin	Intermediate	Arranz A 2001; Horwich A 2000; Motzer RJ 1995
Head and Neck Cancer (Recurrent/Metastatic)	EGFR-inhibitor (cetuximab or panitumumab) and platinum- based chemotherapy	Low	Burtneess B 2005; Vermorken JB 2008; Vermorken JB 2013;
	Pembrolizumab plus platinum- based chemotherapy	Low	Burtneess B 2019;

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023	Effective Date: 08/19/2026
			Last Review Date: 08/19/2026	Frequently Revision: Annual

Non-Hodgkin Lymphoma	Gemcitabine, dexamethasone, and cisplatin ± rituximab	Intermediate	Baetz T 2003; Crump M 2004, 2014
Non-Small Cell Lung Cancer	Cisplatin and vinorelbine	Intermediate	Douillard JY 2006; Fossella F 2003; Gebbia V 2008; Georgoulas V 2005; Kenmotsu H 2020; Pujol JL 2005; Winton T 2005
Non-Small Cell Lung Cancer (Advanced)	Docetaxel	Intermediate	Abe T 2015; Barlesi F 2018; Camps C 2006; Georgoulas V 2004; Gridelli C 2004; Hanna N 2004; Herbst RS 2010; Karampeazis A 2011; Kudoh S 2006; Okamoto I 2020; Paz-Ares L 2008
Non-Small Cell Lung Cancer (Advanced)	Docetaxel and cisplatin	Low	Abe T 2015; Fossella F 2003; Kubota K 2015; Schiller JH 2002
Non-Small Cell Lung Cancer (Advanced)	Docetaxel and ramucirumab	Intermediate	Garon 2014; Yoh 2016
Non-Small Cell Lung Cancer (Metastatic)	Carboplatin/cisplatin, pemetrexed, and pembrolizumab	Low	Gandhi 2018; Langer 2016; Rodrigues-Pereira 2011; Scagliotti 2008
Non-Small Cell Lung Cancer (Metastatic, non-squamous)	Carboplatin, paclitaxel, and atezolizumab ± bevacizumab	Low	Lilenbaum 2005; Ohe 2007; Socinski 2018; Williamson 2005
Non-Small Cell Lung Cancer (Metastatic, squamous)	Carboplatin, paclitaxel/nab-paclitaxel, and pembrolizumab	Low	Gadgeel 2018; Lilenbaum 2005; Ohe 2007; Paz-Ares 2018; Williamson 2005
Ovarian Cancer	Carboplatin and paclitaxel	Low	Clamp 2019; Coleman 2017; Katsumata 2009, 2013; Lhomme 2008; Pignata 2014; Sugiyama 2016; Vasey 2004
Ovarian Cancer (Advanced)	Topotecan	Intermediate	Aoki 2011; Gordon 2001, 2004; Gore 2002; McGonigle 2011; Meier 2009; Sehoul J 2008; Spannuth WA 2007; Swisher 1997
Ovarian Cancer (Advanced)	Carboplatin and docetaxel	High	Vasey 2004; Vorobiof 2003; Wang 2014

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023	Effective Date: 08/19/2026
			Last Review Date: 08/19/2026	Frequently Revision: Annual

Pancreatic Cancer	FOLFIRINOX	Intermediate	Chlorea 2019; Conroy 2011; Conroy 2005; Hosein 2012; Okusaka 2014; Peddi 2012; Suker 2016; Thibodeau 2018; Tong 2018
Small Cell Lung Cancer (Extensive Stage)	Carboplatin, etoposide, and atezolizumab	Low	Horn 2018; Kosmidis 1994; Socinski 2009
Soft Tissue Sarcoma (Advanced)	Doxorubicin	High	Judson I 2014; Lorigan P 2007; Nielsen OS 1998; Seddon B 2017; Tap WD 2017; Tap WD 2020

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 08/19/2026	Effective Date: 08/19/2026 Frequently Revision: Annual
--	--	--	--	---

Reference Information:

1. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
2. Gyawali, B., Bohlke, K., Dickter, J. K., Kelkar, A. H., Knopf, K. B., Rapoport, B. L., Roof, L., Schott, S., Seshadri, M. R., Shilpakar, R., Smith, T. J., Trapani, D., Woodard, A. B., & Cigler, T. (2026). WBC growth factors: ASCO guideline update. *Journal of Clinical Oncology*, 44(9), 812–824. <https://doi.org/10.1200/JCO-25-02938>.
3. ICD10Data.com. (2026). The Web's free 2026 ICD-10-CM/PCS medical coding reference. Retrieved June 29, 2026.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2026 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Updated periodically. Accessed on March 29, 2026.
 - a. Acute Lymphoblastic Leukemia. V2.2025. Revised June 27, 2025.
 - b. Acute Myeloid Leukemia. V3.2026. Revised November 24, 2025.
 - c. Hematopoietic Cell Transplantation. V3.2025. Revised September 24, 2025.
 - d. Hematopoietic Growth Factors. V3.2026. Revised December 5, 2025.
 - e. Hodgkin Lymphoma. V1.2026. Revised October 22, 2025.
 - f. Management of CAR T-Cell and Lymphocyte Engager-Related Toxicities. V2.2026. Revised November 11, 2025.
 - g. Myelodysplastic Syndromes. V3.2026. Revised January 12, 2026.
 - h. Pediatric Aggressive Mature B-Cell Lymphomas. V1.2026. Revised March 20, 2026.
 - i. Pediatric Hodgkin Lymphoma V2.2025. Revised June 9, 2025.
 - j. Neuroblastoma V1.2026. Revised March 16, 2026.
 - k. Wilms Tumor (Nephroblastoma). V2.2025. Revised June 11, 2025
6. Accord BioPharma, Inc. (2026). FILKRI (filgrastim-laha) injection, for subcutaneous or intravenous use: Prescribing information.
7. Spectrum Pharmaceuticals, Inc. (2025). ROLVEDON (eflapegrastim-xnst) injection, for subcutaneous use: Prescribing information.
8. Evive Biotechnology Pte. Ltd. (2023). RYZNEUTA (efbemalenograstim alfa-vuxw) injection, for subcutaneous use: Prescribing information.
9. Partner Therapeutics, Inc. (2022). LEUKINE (sargramostim) for injection, for subcutaneous or intravenous use: Prescribing information.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023	Effective Date: 08/19/2026
			Last Review Date: 08/19/2026	Frequently Revision: Annual

Policy History:

Type of Review	Summary of Changes	P&T Approval Date	UM/CMPC Approval Date
Annual Review	Updated Rolvedon, Ryzneuta, Neupogen, and Neulasta (and biosimilars) criteria with NCCN 2A recommendation for use in prophylaxis of FN due to IEC therapies. Updated Neulasta (and biosimilars) and Neupogen (and biosimilars) criteria with NCCN 2A recommendation for use in those with Pediatric Hodgkin Lymphoma. Updated Granix criteria with NCCN 2A recommendation for use in those with Acute Lymphoblastic Leukemia. Updated Leukine criteria with NCCN 2A recommendation for use in postconsolidation therapy after initial use in high-risk neuroblastoma disease without disease progression. Added Filkri to Neupogen PA criteria. Added new biosimilar Armlupeg to Neulasta criteria. Added override criteria to allow the use of a non-preferred vial agent if the preferred product is only available as a pre-filled pen and does not allow accurate dosing administration of the drug. Added quantity limits table with recommended dosage and limitations. Coding reviewed: added ICD-10 codes and descriptions; added J5111, J5125, J5127, J5130, Q5169. Added Filkri to HCPCS NOC C9399 and J3590. Added Neulasta Onpro to HCPCS J2506. Added Udenyca Onbody to CPT 96377. Added references and incorporated new policy template.	8/14/2026	8/19/2026
Annual Review	Add criteria due to NCCN recommendations for use of Neulasta/Neupogen and their biosimilars or Granix in Classic Hodgkin Lymphoma. Add NCCN recommendation for use of Neulasta/ Neupogen in Pediatric Aggressive Mature B-cell lymphomas Add NCCN 2A recommendation for use of Neupogen in relapsed or refractory adult ALL in combination with FLAG or FLAG-IDA. Add NCCN 2A recommendation for use of Granix in H-ARS (similar to other G-CSFs). Add references. Update table for FN risk. NCCN updated the risk association for FN in ovarian cancer with docetaxel and carboplatin to high from intermediate risk. Wording and formatting updates. Coding Reviewed: Removed HCPCS C9173 effective 7/1/25.	9/5/2025	9/16/2025
Annual Review	- Add combination use of Mozobil (plerixafor) with Leukine (Sargramostim) for use in treatment for hematopoietic cell mobilization. Clarify existing language for use in combination with Mozobil in filgrastim, pegfilgrastim, and tbo-filgrastim criteria. - Add criteria to stipulate liver dysfunction risk factor for febrile neutropenia can be 2X ULN for either AST or ALT levels Rolvedon and Ryzneuta: Add NCCN criteria for use in Hematopoietic Syndrome of Acute Radiation Syndrome.	11/18/2024	12/17/2024

Utilization Management and Clinical Medical Policy

Policy Name: Colony Stimulating Factors	Policy Number: MP-RX-FP-18-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023	Effective Date: 08/19/2026
			Last Review Date: 08/19/2026	Frequently Revision: Annual

	- Remove may not be approved criteria for “Individual is using for prophylaxis of FN during concomitant chemotherapy and radiation therapy”. - Neupogen: Add criteria for use in IPSS-R risk myelodysplastic syndrome associated with symptomatic anemia. Clarify criteria for use in hematopoietic cell mobilization. Add criteria for use in combination with plerixafor when used for insufficient collection of stem cells following prior filgrastim therapy (alone or in combination). Add criteria for use in hematopoietic cell mobilization for allogenic donors as a single agent. Add criteria for use as supportive management of neutropenic events due to immunotherapy related toxicities from CAR-T cell therapy. - Leukine: Add criteria for use in hematopoietic cell mobilization in combination with cyclophosphamide with or without plerixafor. Clarify existing criteria for use in r/r high-risk neuroblastoma in combination with Unituxin (dinutuximab). - Granix: Add criteria for use in IPSS-R risk myelodysplastic syndrome associated with symptomatic anemia. Add definition for “older adult” in FN Risk table for use in Breast cancer for adjuvant TC. - Add Appendix table: Febrile Neutropenia Risk of Selected Chemotherapy Regimens Coding Reviewed: Add new FDA approved Udenyca Onbody to the PA, ST, and QL. Added Udenyca Onbody to HCPCS J3490, J3590. Effective 4/1/2024 Added Udenyca Onbody to Q5111. Minor updates to HCPCS code descriptions. Removed Prokinexa from HCPCS J2820. Effective 7/1/2024 CMS update: Remove HCPCS J3490 and J3590 for Ryzneuta. Add HCPCS J9361 for Ryzneuta. Add HCPCS C9399 and J3590 for Nypozi.			
Policy Inception	Elevance Health’s Medical Policy adoption	N/A		11/30/2023